Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACiE for Locally Advanced Gastric and GEJ Adenocarcinoma
NCT05396326Phase 1Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin and tegafur in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Incidence of Treatment Related Adverse Events. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
oxaliplatintegafur
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05396326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396326.